id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-280571-ntgt5hy9	Ginocchio, Christine C.	Strengths and Weaknesses of FDA-Approved/Cleared Diagnostic Devices for the Molecular Detection of Respiratory Pathogens	2011-05-01		.txt	text/plain	7521	341	39	In addition to RADTs, there are U.S. Food and Drug Administration (FDA)-approved/cleared nonmolecular-based viral diagnostic methods with a more rapid time to result, compared with traditional viral tube culture, eg, direct fluorescent antibody (DFA) testing and rapid cell culture. Although these 8 viruses are responsible for a large number of respiratory tract infections, bocavirus, selected coronaviruses (229E, OC43, NL63, and HKU-1), parainfluenza 4, and rhinovirus are also important causes of respiratory disease and are generally only detected using NAATs. Because antiviral therapies are currently limited to the treatment of influenza A, influenza B, cytomegalovirus pneumonia, and varicella zoster virus pneumonia, it is often argued that the specific identification of other viruses is not relevant, because the information would not change patient management. With clinical integration of real-time polymerase chain reaction (PCR) and FDA-approved/cleared simple cartridge-based NAATs, laboratories of all sizes are now able to perform molecular diagnostic tests.	./cache/cord-280571-ntgt5hy9.txt	./txt/cord-280571-ntgt5hy9.txt